Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 5;11(12):1950. doi: 10.3390/cancers11121950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Relative risk (RR) of “cough” adverse events; all grades. Combined RR for all studies was 1.24 (95% CI 0.64–2.39), showing no significant difference in risk of cough between combination and monotherapy. Dabrafenib plus trametinib in the Robert study had an RR of 2.02 (95% CI 1.38–2.97), revealing a significantly larger risk of cough as compared to vemurafenib monotherapy. Encorafenib plus binimetinib in the Dummer study and Vemurafenib plus cobimetinib in the Ascierto study did not show any significant difference in risk of cough compared to vemurafenib monotherapy.